Ponatinib (AP24534) is an oral multi-targeted tyrosine kinase inhibitor developed for treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.38, 39 This BCR-ABL inhibitor is used as second-line treatment for patients who have acquired resistance to standard therapy. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.